Glucagon-like peptide-1: the basis of a new class of treatment for type 2 diabetes.
about
Design and synthesis of 4-(2,4,5-trifluorophenyl)butane-1,3-diamines as dipeptidyl peptidase IV inhibitorsGlucagon-Like Peptide-1 and Its Class B G Protein-Coupled Receptors: A Long March to Therapeutic SuccessesIndividualized therapy for type 2 diabetes: clinical implications of pharmacogenetic data.Development of a robust QSAR model to predict the affinity of pyrrolidine analogs for dipeptidyl peptidase IV (DPP- IV).Efficacy of liraglutide in a real-life cohort.The human glucagon-like peptide-1 analogue liraglutide preserves pancreatic beta cells via regulation of cell kinetics and suppression of oxidative and endoplasmic reticulum stress in a mouse model of diabetes.Protein tyrosine phosphatase 1B inhibitors: a molecular level legitimate approach for the management of diabetes mellitus.Novel exenatide analogs with peptidic albumin binding domains: potent anti-diabetic agents with extended duration of actionDesign, synthesis, biological screening, and molecular docking studies of piperazine-derived constrained inhibitors of DPP-IV for the treatment of type 2 diabetes.A Hamster Model of Diet-Induced Obesity for Preclinical Evaluation of Anti-Obesity, Anti-Diabetic and Lipid Modulating AgentsInjectable protease-operated depots of glucagon-like peptide-1 provide extended and tunable glucose control.Autonomic nervous system-dependent and -independent cardiovascular effects of exendin-4 infusion in conscious rats.Is Glucagon-like peptide-1, an agent treating diabetes, a new hope for Alzheimer's disease?A retrospective audit of type 2 diabetes patients prescribed liraglutide in real-life clinical practice.Insulin degludec/liraglutide (IDegLira) for the treatment of type 2 diabetesCombination therapy with liraglutide and insulin in Japanese patients with type 2 diabetes: A 36-week, randomized, double-blind, parallel-group trial.Glucagon-Like Peptide-1 Receptor Agonists for Type 2 Diabetes: A Clinical Update of Safety and Efficacy.Incretin-based therapies for type 2 diabetes mellitus: current status and future prospects.Novel GLP-1 receptor agonists for diabetes.Commonality between diabetes and Alzheimer's disease and a new strategy for the therapyAdministration of an acylated GLP-1 and GIP preparation provides added beneficial glucose-lowering and insulinotropic actions over single incretins in mice with Type 2 diabetes and obesity.Novel hydrazine derivatives as selective DPP-IV inhibitors: findings from virtual screening and validation through molecular dynamics simulations.Efficacy and safety of fixed-ratio combination of insulin degludec and liraglutide (IDegLira) for the treatment of type 2 diabetes.Effects of nitric oxide synthase inhibition with or without cyclooxygenase-2 inhibition on resting haemodynamics and responses to exendin-4.A depot-forming glucagon-like peptide-1 fusion protein reduces blood glucose for five days with a single injection.Monotreme glucagon-like peptide-1 in venom and gut: one gene - two very different functions.Liraglutide, a long-acting GLP-1 mimetic, and its metabolite attenuate inflammation after intracerebral hemorrhage.Influence of selective fluorination on the biological activity and proteolytic stability of glucagon-like peptide-1.Design, synthesis, biological evaluation, and docking studies of (s)-phenylalanine derivatives with a 2-cyanopyrrolidine moiety as potent dipeptidyl peptidase 4 inhibitors.Diabetes: the latest developments in inhibitors, insulin sensitisers, new drug targets and novel approaches. October 18-19, 2004, The Hatton, London, UK.Dogfish glucagon analogues counter hyperglycaemia and enhance both insulin secretion and action in diet-induced obese diabetic mice.StraPep: a structure database of bioactive peptides.
P2860
Q27684616-B5477F57-80F3-4A52-AA30-B4A6FFAB1E1BQ28067465-06747F91-5D6C-4CEF-B696-F11E53A21DC0Q30571118-7E0F120E-3624-45D8-A482-8B66CC95B761Q30998308-DE0BE9D6-B99C-4C4F-90CE-012FE63CC7B4Q33785111-E45CDC5A-D5F3-440E-93D0-63D0B6A9DC46Q33826388-EAFA5F8C-C2A4-4545-A9E5-672377D2E323Q34135843-2C6B9781-6C76-446F-B271-F7E3752700B3Q35087618-328A9FE2-63F6-4A6B-B5BE-8591BF652178Q35250506-F4BC9251-130F-4BDF-8F23-74A8FBD78159Q35743729-2863C76A-27BB-4974-BDB1-3E295EFACB33Q36637567-F6672778-5583-4C79-9F93-38D438F204B5Q36735857-87D595CB-4D08-4B6E-91FB-071E61A6E2F4Q36860616-CBD1BF1C-4100-4ECE-A8A5-673FD4A1DD47Q36941700-2C8F0ADC-0499-4D6B-9242-CB5A8F1D8451Q36971833-A8FA90CD-137D-4D9E-9C36-2F884775EE16Q37060864-DF8C90DB-AD28-4123-B059-C597A2C5BCD2Q37402786-3025654C-4181-47B3-85FC-44317F75E6A8Q37760515-2FDA3056-2E54-43D9-988A-0267EBCB44C9Q37960149-453D5261-5F33-4683-99FF-EF5A404D3CECQ38253931-54EE43DB-43CB-41D1-8613-5DAA43A45E52Q38337206-13E669B3-DD03-4BD2-BFD3-7A1822A951E6Q38398676-215CBA8C-F8E6-43EA-98F6-AB4F19AC571DQ39115000-DE3BA1B1-FBBC-451D-A2B6-7639C4B805C5Q41603681-2801A701-7155-48D3-9DEA-4EF8014E5185Q42280003-05944A37-9553-4665-AC83-C547800EF008Q42362229-DC6CDB6A-54BF-4647-9689-FCE92F9B5F47Q42406502-0367DB59-5679-45DE-8781-2CAE92CDA3C4Q43177381-5BDF0703-B8B8-4B81-BFB5-4BDE988A9651Q46415265-22668186-0D2B-4EF8-A340-E0CE0298D849Q50762531-5A2F997E-7CA3-484A-9BAA-FF493F36ABBCQ51282489-7ED8BC8E-1C62-4337-BDE7-782C55CD7278Q52567287-B23DAECE-DAA9-4973-910C-36166A855C7B
P2860
Glucagon-like peptide-1: the basis of a new class of treatment for type 2 diabetes.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Glucagon-like peptide-1: the basis of a new class of treatment for type 2 diabetes.
@ast
Glucagon-like peptide-1: the basis of a new class of treatment for type 2 diabetes.
@en
type
label
Glucagon-like peptide-1: the basis of a new class of treatment for type 2 diabetes.
@ast
Glucagon-like peptide-1: the basis of a new class of treatment for type 2 diabetes.
@en
prefLabel
Glucagon-like peptide-1: the basis of a new class of treatment for type 2 diabetes.
@ast
Glucagon-like peptide-1: the basis of a new class of treatment for type 2 diabetes.
@en
P356
P1476
Glucagon-like peptide-1: the basis of a new class of treatment for type 2 diabetes
@en
P2093
Lotte Bjerre Knudsen
P304
P356
10.1021/JM030630M
P407
P577
2004-08-01T00:00:00Z